NWPHF

Healthcare Biotechnology

Newron Pharmaceuticals S.p.A.

$20.00

+0.00 +0.00% today

Price History

Not enough data

Key Stats

Market Cap

408.95M

Avg Volume

EPS

-$0.74

52W High

$20.00

52W Low

$9.36

Div. Yield

0.0%

Valuation

P/B Ratio

-31.68

P/S Ratio

39.26

EV/EBITDA

-18.67

EV/Revenue

40.54

Margins

Gross Margin 100.0%

Operating Margin (520.5%)

Net Margin (283.6%)

EBITDA Margin (217.1%)

Growth & Returns

Revenue Growth (YoY)

(73.2%)

Return on Assets

(27.8%)

Liquidity & Leverage

Current Ratio

3.15

Quick Ratio

2.89

Total Cash

32.89M

Total Debt

39.04M

About

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.